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Association of Hippocampal AtrophyWith Duration
of Untreated Psychosis andMolecular Biomarkers During
Initial Antipsychotic Treatment of First-Episode Psychosis
Donald C. Goff, MD; Botao Zeng, MD, PhD; Babak A. Ardekani, PhD; Erica D. Diminich, PhD; Yingying Tang, PhD;
Xiaoduo Fan, MD; Isaac Galatzer-Levy, PhD; Chenxiang Li, MS; Andrea B. Troxel, ScD; JijunWang, MD, PhD
IMPORTANCE Duration of untreated psychosis (DUP) has been associated with poor
outcomes in schizophrenia, but themechanism responsible for this association is not known.
OBJECTIVES To determine whether hippocampal volume loss occurs during the initial 8
weeks of antipsychotic treatment and whether it is associated with DUP, and to examine
molecular biomarkers in association with hippocampal volume loss and DUP.
DESIGN, SETTING, AND PARTICIPANTS A naturalistic longitudinal studywithmatched healthy
controls was conducted at Shanghai Mental Health Center. BetweenMarch 5, 2013, and
October 8, 2014, 71 medication-naive individuals with nonaffective first-episode psychosis
(FEP) and 73 age- and sex-matched healthy controls were recruited. After approximately 8
weeks, 31 participants with FEP and 32 controls were reassessed.
EXPOSURES The participants with FEP were treated according to standard clinical practice
with second-generation antipsychotics.
MAIN OUTCOMES ANDMEASURES Hippocampal volumetric integrity (HVI) (an automated
estimate of the parenchymal fraction in a standardized hippocampal volume of interest),
DUP, 13 peripheral molecular biomarkers, and 14 single-nucleotide polymorphisms from 12
candidate genes were determined.
RESULTS The full sample consisted of 71 individuals with FEP (39 women and 32men; mean
[SD] age, 25.2 [7.7] years) and 73 healthy controls (40women and 33men; mean [SD] age,
23.9 [6.4] years). Baseline median left HVI was lower in the FEP group (n = 57) compared
with the controls (n = 54) (0.9275 vs 0.9512; difference in point estimate, −0.020 [95% CI,
−0.029 to −0.010]; P = .001). During approximately 8 weeks of antipsychotic treatment, left
HVI decreased in 24 participants with FEP at a median annualized rate of −.03791 (–4.1%
annualized change from baseline) compared with an increase of 0.00115 (0.13% annualized
change from baseline) in 31 controls (difference in point estimate, −0.0424 [95% CI, −0.0707
to −0.0164]; P = .001). The change in left HVI was inversely associated with DUP (r = −0.61;
P = .002). Similar results were found for right HVI, although the association between change
in right HVI and DUP did not achieve statistical significance (r = −0.35; P = .10). Exploratory
analyses restricted to the left HVI revealed an association between left HVI andmarkers of
inflammation, oxidative stress, brain-derived neurotrophic factor, glial injury, andmarkers
reflecting dopaminergic and glutamatergic transmission.
CONCLUSIONS AND RELEVANCE An association between longer DUP and accelerated
hippocampal atrophy during initial treatment suggests that psychosis may have persistent,
possibly deleterious, effects on brain structure. Additional studies are needed to replicate
these exploratory findings of molecular mechanisms by which untreated psychosis may
affect hippocampal volume and to determine whether these effects account for the known
association between longer DUP and poor outcome.
JAMA Psychiatry. 2018;75(4):370-378. doi:10.1001/jamapsychiatry.2017.4595
Published online February 21, 2018.
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H ippocampal volume reduction is prominent inschizophrenia,1,2 correlateswithpooroutcome,3-5 andhasbeen linkedtoearlyprogressionof illness.6,7A long
duration of untreated psychosis (DUP) is also associatedwith
poor outcome,8 but a biological basis for this association has
not been identified, to our knowledge.9 Several factors, in-
cludingelevatedcortisol levels, inflammation,oxidativestress,
decreased neurotrophic factors, and glutamatergic excito-
toxic effects, have been linked to early psychosis10 and could
mediate an association between DUP and hippocampal vol-
ume loss, but evidence from longitudinal studies is lacking.
Whereas the negative association of DUPwith clinical course
is attenuated by the initiation of antipsychotic treatment, the
evidence is mixed as to whether antipsychotics contribute to
loss of brain volume or protect against it.11,12 Hence, the de-
gree to which loss of brain volume early in treatment reflects
an illness effect, a drug effect, or both is not known.
To address the question ofwhether hippocampal volume
reductionoccursearly in treatmentand isassociatedwithDUP,
we measured hippocampal volumetric integrity (HVI) (in-
versely associatedwith hippocampal atrophy)13,14 before and
after initial antipsychotic treatment in medication-naive pa-
tients with first-episode psychosis (FEP) and in matched
healthy controls. We hypothesized that HVI would be re-
duced at baseline in participants with FEP relative to con-
trols, would decrease at a faster rate, andwould be correlated
with DUP. As an exploratory approach, we alsomeasured pe-
ripheral biomarkers that reflect factors hypothesized to affect
hippocampal volume in schizophrenia andexaminedwhether
these biomarkers interact with DUP to predict HVI.
Methods
Study Design and Setting
BetweenMarch5, 2013, andOctober 8, 2014, individualswith
nonaffective FEP were recruited from the Shanghai Mental
HealthCenterearlypsychosisprogram.Healthycontrolsgroup-
matched by sex, age, and educational level were recruited by
advertisement. All participantswereMandarin-speakingHan
Chinese individuals living in the Shanghaimetropolitan area.
Eligible participantswith FEPmet the criteria for schizophre-
niaor schizophreniformdisorderbasedontheStructuredClini-
cal Interview for DSM-IV-TR,15 were medication naive, were
experiencing a first episodeofpsychosis, anddidnotmeet the
criteria for anyotherAxis I disorder.Healthy controlswere as-
sessed using the Structured Clinical Interview forDSM-IV-TR
(nonpatient version) to exclude any Axis I disorder and were
also psychotropicmedication naive. All participantswere be-
tween the ages of 16 and 40 years; were right-handed; com-
pleted at least 9 years of school;were free of substance abuse,
suicidal ideation,andunstablemedical illness; andhadnocon-
traindications tomagnetic resonance imaging. After baseline
assessments, participants with FEP were treated by their cli-
nicians with second-generation antipsychotics according to
standardclinical practice (eAppendix 1 in theSupplement) and
were invited to return for clinical assessment and magnetic
resonance imaging after 8 weeks. Matched healthy controls
were also invited to return at 8 weeks for a follow-up evalua-
tion. Participants with FEP who were outpatients were con-
tacted weekly by telephone to reinforce medication adher-
ence; baseline and follow-up visits were scheduled as closely
as possible to 8 weeks apart. The study protocol was ap-
provedby the ShanghaiMentalHealthCenter institutional re-
view board and the New York University Medical Center in-
stitutional reviewboard, andall participants providedwritten
informed consent.
StudyMeasures
Theprimaryoutcomewas annualized change inHVI. Because
the left and right hippocampi are asymmetrical in volume16,17
andmaydiffer invulnerability todisease,18weexaminedboth
left HVI (LHVI) and right HVI (RHVI). Participants with FEP
and controls underwent imaging at Shanghai Mental Health
Center at baseline and after approximately 8weeks on a 3.0-T
SiemensVeriomagnetic resonance imaging scanner (Siemens)
with a 32-channel head coil (eAppendix 2 in the Supplement).
Hippocampalvolumetric integrity,definedas theparenchymal
fraction of a standardized volume of interest that is expected
to encompass the hippocampus in a healthy brain,was calcu-
lated using a fully automated procedure inwhich the volume
of interest isestimatedforeachhemisphereusingautomatically
detected landmarks and the tissue fraction is estimated by
histogram analysis14 (eAppendix 3 in the Supplement). This
procedure has demonstrated excellent test-retest reliability
(intraclass correlation coefficient, 0.998) and superior perfor-
mance comparedwithFreeSurfer, version 5.3.0, in differenti-
ating individualswithAlzheimerdisease fromhealthyage-and
sex-matched controls on the basis of hippocampal volume
change.13,14 To compare approaches, measurement of hippo-
campal volume was also performed using the longitudinal
streamofFreeSurfer, version6.All participants received a full
psychiatric and medical screening by a research psychiatrist
(B.Z.) (eAppendix4 in the Supplement), including calculation
of DUPbased onhistory provided by the participant and fam-
ilymembers. Duration of untreated psychosis was defined as
the number of weeks elapsed since the onset of at least 1 per-
sistentpsychoticsymptomofmoderateorgreaterseverity.19Par-
ticipantswithFEPalso completed theBrief Psychiatric Rating
Key Points
Question Does hippocampal volume loss occur during initial
antipsychotic treatment and is it associated with duration of
untreated psychosis?
Findings In this longitudinal case-control study of individuals with
first-episode nonaffective psychosis before and after initiation of
antipsychotic medication, patients had significantly greater
hippocampal atrophy compared with healthy controls at baseline.
Moreover, at 8-week follow-up, hippocampal atrophy increased to
a greater extent in patients compared with healthy controls, and
the rate of progression of left hippocampal atrophy was
significantly correlated with the duration of untreated psychosis.
Meaning Early hippocampal volume loss may play a role in
mediating the association between duration of untreated
psychosis and poor outcomes in schizophrenia.
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Scale(BPRS)20andScaleforAssessmentofNegativeSymptoms21
administered by a single postdoctoral rater at baseline and 8
weeks. All participants completed the MATRICS Consensus
Cognitive Battery22 at baseline and 8weeks.
Molecular Biomarkers
Fasting blood samples and 3 saliva samples (collected in the
morning, at noon, and in the evening) were obtained at
baseline from the participants with FEP and controls and at
week 8 from the participants with FEP (eAppendices 5-8 in
the Supplement). Plasma biomarkers were selected to mea-
sure inflammation (C-reactive protein, interleukin 1B, inter-
leukin 8 [IL-8], tumor necrosis factor, and interferon γ
[IFN-γ]23,24 values), oxidative stress (thioredoxin25 and
S100 calcium binding protein B [S100B]26 values), excito-
toxicity (glutamate, aspartate,6 and homocysteine27,28 con-
centrations), brain-derived neurotrophic factor (BDNF)
levels,29,30 stress (salivary cortisol levels),23 and mitochon-
drial injury (lactate values31). Genotyping included 14
single-nucleotide polymorphisms associated with these
pathways (eAppendix 9 in the Supplement).
Statistical Analysis
Statistical analyses were performed with SPSS software, ver-
sion 23.0 (IBM Corp) and JMP Pro, version 12.2.0 (SAS Insti-
tute). All data were tested for normality of distribution using
theKolmogorov-Smirnov test. Duration of untreated psycho-
sis, HVI, and serum biomarkers were not normally distrib-
uted. To examine between-groupmedian differences in HVI,
we used a Mann-Whitney test. To explore potential associa-
tions between DUP and biomarkers, we used Spearman rank
order correlations. Normally distributed data were evaluated
using thePearsoncorrelationcoefficient, independentsamples
t tests, and χ2 tests for independence. Because 4 participants
received medication briefly before biomarker collection, a
sensitivity analysis was performed by excluding participants
who were not medication free at the time of assessment.
Because the interval between imaging differed between indi-
viduals, the change from baseline in HVIwas converted to an
annualized rate of change.
Two primary analyses were performed: comparison of
HVI between groups at baseline and comparison of the
annualized rate of change in HVI from baseline to follow-up
between groups. Secondary analyses examined correlations
between DUP and baseline HVI and between DUP and
change in HVI. Confirmatory analyses were performed to
examine the association of laterality with baseline HVI and
change in HVI (eAppendix 10 in the Supplement). Addi-
tional exploratory analyses to assess associations between
clinical measures, biomarkers, and HVI were performed
without correction for multiple comparisons. These analy-
ses were restricted to the LHVI to minimize type I error.
Given the large number of predictors, and to avoid model
overfitting, we applied least absolute shrinkage and selec-
tion operator (LASSO) regression32 (eAppendix 11 in the
Supplement) and limited biomarkers for multivariate mod-
eling to those that were associated with baseline LHVI or
with change in LHVI at P < .10. Least absolute shrinkage and
selection operator regression is a modified form of
least-squares regression that shrinks noninfluential
coefficients to zero, excluding them from the final model.
This approach was used owing to its robustness under
conditions of nonnormality and large variable to sample
size ratios, which allow for the examination of multiple
interactions while minimizing the risk of type I error.33
For the 2 primary analyses, P < .03 (2-tailed) was considered
significant.
Results
Enrollment and Retention of Participants
A total of 71 patients with FEP (19 inpatients and 52 outpa-
tients) and 73 matched healthy controls met the inclusion
criteria and were enrolled in the study. Participants with
FEP and their parents reported fewer years of education,
and participants with FEP had lower rates of employment
and marriage and lower MATRICS Consensus Cognitive Bat-
tery composite scores compared with controls (Table 1). A
total of 31 participants with FEP and 32 controls completed
week 8 assessments. Dropout rates were 32% for inpatients
with FEP (6 of 19) and 65% for outpatients with FEP (34 of
52); 18 participants with FEP refused the offer for a second
assessment, 15 outpatients were unable to travel back to
Shanghai Mental Health Center for follow-up assessment,
and 7 were unavailable for follow-up. Individuals with FEP
who completed the study had higher BPRS total scores and
BPRS agitation subscale scores at baseline compared with
individuals with FEP who did not complete the study
(eTable 1 in the Supplement). At baseline, 57 participants
with FEP and 54 controls had imaging results that met qual-
ity standards (eTable 2 in the Supplement); 24 participants
with FEP and 32 controls had imaging results at both base-
line and follow-up that met quality standards (eTables 2 and
3 in the Supplement). An image analysis expert (B.A.A.)
blinded to group status performed quality control for HVI
analysis by visual inspection for motion and other artifacts
(eAppendix 12 in the Supplement).
HVI and DUP
At baseline, 57 participants with FEP had lower median
LHVI (0.9275 [interquartile range (IQR), 0.8256-0.9689] vs
0.9512 [IQR, 0.8501-0.9825]; P = .001) and lower RHVI
(0.9237 [IQR, 0.8525-0.9661] vs 0.9412 [IQR, 0.8681-
0.9690]; P = .001) compared with 54 controls (Table 2; eFig-
ures 1 and 2 in the Supplement). The change in LHVI and
RHVI from baseline to follow-up in the controls did not dif-
fer significantly from zero. In the participants with FEP,
LHVI decreased at a median annualized rate of −4.1%, and
RHVI decreased at a median annualized rate of −3.3%,
which differed significantly from the control group
(P = .001; eFigures 3-6 in the Supplement). At baseline, nei-
ther LHVI (r = 0.04; P = .80) nor RHVI (r = 0.07; P = .64)
was significantly correlated with DUP; however, DUP was
significantly correlated with the reduction from baseline to
follow-up in LHVI (r = −0.61; P = .002) (Figure 1), but not
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with the change in RHVI (r = −0.35; P = .10). The effect of
laterality was not significant for any HVI finding in partici-
pants with FEP, but baseline RHVI was larger than LHVI in
controls (eAppendix 10 in the Supplement). Left and right
hippocampal volume as measured by the longitudinal
stream of FreeSurfer, version 6, did not differ between
groups at baseline, nor did change in hippocampal volume
at follow-up (eTable 4 in the Supplement).
Peripheral Biomarkers
At baseline, median plasma aspartate and salivary cortisol
concentrations were elevated in participants with FEP com-
pared with controls; no other biomarker differed signifi-
cantly between groups (Table 1). Results did not differ when
analysis was restricted to participants with FEP who were
medication free at the time that blood samples were
obtained (eTable 5 in the Supplement). Plasma aspartate
and homocysteine concentrations increased at follow-up in
participants with FEP, although the elevation in aspartate
concentrations was not significant when the analysis was
restricted to participants with FEP who were medication
free at baseline (eTable 6 in the Supplement) and no differ-
ence between groups in biomarkers at baseline or after
treatment would survive correction for multiple compari-
sons. Change in homocysteine concentrations was associ-
ated with change in S100B (r = 0.52; P = .004), IFN-γ
(r = 0.54; P = .002), IL-8 (r = 0.47; P = .009), and tumor
necrosis factor (r = 0.41; P = .03) concentrations but was not
significantly associated with change in LHVI.
Antipsychotic Effects
After a mean duration of 62 days of antipsychotic treat-
ment, individuals with FEP who completed the study
showed significant improvement on the BPRS total score,
the BPRS positive subscale score, the BPRS agitation sub-
scale score, and the MATRICS Consensus Cognitive Battery
composite score (eTable 7 in the Supplement). Mean daily
antipsychotic dose was not significantly associated with
DUP or with baseline HVI or change in HVI (eTable 8 in the
Supplement).
Table 1. Baseline Characteristics of Study Participants
Characteristic
Total
No.
Participants
With FEPa
Total
No.
Healthy
Controlsa
Test
Statistic P Value
Age, mean (SD), y 71 25.2 (7.7) 73 23.9 (6.4) t = 1.13 .26
Women, No. (%) 71 39 (55) 73 40 (55) χ 21 = .012 .52
Educational level,
mean (SD), y
71 12.0 (3.1) 73 12.9 (2.3) t = −1.95 .05
Parental educational level, mean (SD), y 71 8.0 (5.8) 73 10.0 (4.1) t = −2.36 .02
Married, No. (%) 71 17 (24) 73 19 (26) χ 21 = .059 .48
Employed, No. (%) 71 15 (21) 73 34 (47) χ 22 = 11.61 .003
Tobacco use, No. (%) 71 2 (3) 73 0 χ 22 = 3.30 .19
DUP, mean (SD), wk 61 25.4 (21.6) NA NA NA NA
BPRS total score, mean (SD) 70 48.01 (10.97) NA NA NA NA
BPRS agitation subscale score, mean (SD) 70 9.54 (4.24) NA NA NA NA
BPRS positive subscale score, mean (SD) 70 19.11 (4.80) NA NA NA NA
BPRS negative subscale score, mean (SD) 70 5.81 (3.27) NA NA NA NA
SANS composite score, mean (SD) 70 20.74 (17.95) NA NA NA NA
MCCB composite score, mean (SD) 69 35.43 (13.69) 66 45.09 (9.43) t = 4.79 .001
CRP, median (IQR), FI 69 7631.41 (6778.62-9456.46) 61 7610.07 (6937.90-9025.92) U = 2065 .85
IL-1B, median (IQR), FI 69 68.82 (35.35-166.58) 61 76.77 (44.41-225.11) U = 1902 .34
IL-8, median (IQR), FI 69 71.30 (49.79-83.26) 61 63.41 (50.77-82.46) U = 2034 .74
IFN-γ, median (IQR), FI 69 89.42 (70.87-113.86) 61 88.96 (64.69-131.47) U = 2054 .81
TNF, median (IQR), FI 69 93.60 (76.02-105.44) 61 92.03 (74.28-103.94) U = 1984 .57
Salivary cortisol, median (IQR), μg/dL 46 0.24 (0.15-0.33) 54 0.18 (0.12-0.27) U = 910 .02
Aspartate, median (IQR), nmol/mL 69 134.32 (86.67-198.31) 61 102.32 (79.33-141.65) U = 1666 .04
Glutamate, median (IQR), nmol/mL 69 111.00 (98.20-128.00) 61 105.00 (92.00-121.60) U = 1845 .23
Lactate, median (IQR), mg/dL 69 15.08 (11.27-20.34) 60 13.28 (9.83-17.75) U = 1770 .16
HCY, median (IQR), mg/L 69 0.65 (0.61-0.71) 61 0.65 (0.60-0.73) U = 2091 .95
BDNF, median (IQR), FI 69 340.83 (142.52-340.83) 62 287.37 (145.99-722.44) U = 2009 .55
Thioredoxin, median (IQR), pg/mL 69 420.17 (323.58-609.50) 61 492.33 (324.17-637.67) U = 1956 .49
S100B, median (IQR), FI 69 125.13 (69.76-211.93) 61 130.44 (61.14-265.52) U = 2044 .79
Abbreviations: BDNF, brain-derivedneurotrophic factor; BPRS,Brief Psychiatric
RatingScale;CRP,C-reactiveprotein;DUP,durationofuntreatedpsychosis;FEP, first
episode of psychosis; FI, fluorescence intensity; HCY, homocysteine; IL, interleukin;
IFN-γ, interferonγ; IQR, interquartile range;MCCB,MATRICSConsensusCognitive
Battery;NA, not applicable; SANS, Scale forAssessmentofNegative Symptoms;
S100B, S100calciumbindingproteinB; TNF, tumornecrosis factor.
SI conversion factor: To convert lactate to millimoles per liter, multiply by 0.111.
a Comparisons between participants with FEP and healthy controls were
adjusted for parental educational level.
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Associations Between LHVI, Biomarkers,
and Clinical Variables
In participants with FEP, baseline LHVI was significantly
correlated with RHVI (r = 0.72; P < .001), with the BPRS
total score (r = −0.33; P = .014), and with the BPRS agitation
subscale score (r = −0.31; P = .021) (eTable 9 in the Supple-
ment). The change in LHVI was inversely associated with
the BPRS agitation subscale score (r = −0.45; P = .03) and
with change in the BPRS negative symptoms subscale score
(r = −0.41; P = .05), such that greater baseline agitation and
less response of negative symptoms were associated with
greater reduction in LHVI (eTable 10 in the Supplement).
However, correlations between clinical variables and LHVI
would not survive correction for multiple comparisons.
Significant results of the LASSO regression models are
summarized in Table 3; complete results can be found in
eTables 11 and 12 in the Supplement, and correlational
results from which factors for the LASSO regression were
selected can be found in eTables 13 and 14 in the Supple-
ment. In the first model, significant main effects associated
with baseline LHVI included INF-γ, IL-8, BDNF GG genotype,
and nitric oxide synthase 1 (NOS1) CC genotype. Significant
interactions with DUP associated with baseline LHVI were
found for INF-γ, IL-8, NOS1 CC genotype, BDNF AA geno-
type, zinc finger protein 804A (ZNF804A) GG genotype, and
catechol-O-methyltransferase (COMT) GA genotype. In the
second model, a significant main effect associated with the
change in LHVI was found for S100B; interactions between
DUP and S100B, thioredoxin, and NOS1 CC genotype were
also associated with change in LHVI.
Discussion
Left hippocampal volumetric integrity and RHVI were re-
ducedatbaseline inparticipantswithFEPcomparedwith con-
trols and decreased further during 8weeks of treatment; this
reduction in LHVI during treatmentwas correlatedwithDUP.
Our exploratory analysis identified several biomarkers andge-
netic markers that interacted with DUP and were associated
with baseline LVHI andwith the change in LHVI during treat-
ment. However, none of the plasma biomarkers that were as-
sociated with LHVI differed between patients with FEP and
controls at baseline or significantly changed with treatment,
so the factors that we identified as possible mediators of the
effect of untreated psychosis onhippocampal volume are not
clearly associated with illness or treatment.
Hippocampal Volumetric Integrity
Previous studies have not found consistent evidence of pro-
gressive hippocampal volume loss after onset of illness.34We
found a median annualized rate of LHVI reduction of 4.1%,
whereas themean annualized reductionwas 6.2%, reflecting
the effect of 2 outliers with annualized LHVI reductions of
20.6% and 29.1% (Figure 2; eFigure 3 in the Supplement). Al-
though the annualized rate of change in LHVI was used as a
standardized unit of measure, we do not know if this rate of
change would remain constant beyond the 8-week interval
measured inthisstudy.Ourdetectionofsignificantchangewith
our automated measure of HVI and not with hippocampal
Table 2. Comparisons Between Groups: Baseline,Week 8, and Change in Hippocampal Volumetric Integrity
Characteristic
Total
No.
Participants With FEP,
Median (IQR)
Total
No.
Healthy Controls,
Median (IQR)
Test
Statistic P Value
Effect
Size (r)a
Baseline LHVI 57 0.9275 (0.8256 to 0.9689) 54 0.9512 (0.8501 to 0.9825) 841.00 .001 .391
Baseline RHVI 57 0.9237 (0.8525 to 0.9661) 54 0.9412 (0.8681 to 0.9690) 967.00 .001 .320
Baseline LHVI (completers) 24 0.9323 (0.8343 to 0.9789) 31 0.9633 (0.9138 to 0.9876) 157.00 .001 .481
Baseline RHVI (completers) 24 0.9277 (0.8623 to 0.9678) 31 0.9537 (0.8795 to 0.9722) 445.00 .001 .476
Week 8 LHVI 24 0.9297 (0.8083 to 0.9763) 32 0.9636 (0.9149 to 0.9908) 111.00 .001 .654
Week 8 RHVI 24 0.9239 (0.8575 to 0.9597) 32 0.9548 (0.8795 to 0.9722) 88.50 .001 .604
Median annualized change in LHVI 24 −0.03791 (−0.0758 to 0.0049) 31 0.001151 (−0.0165 to 0.0207) 179.00 .001 .441
Median annualized change in RHVI 24 −0.03027 (−0.0817 to 0.00004) 31 0.004535 (−0.0151 to 0.0350) 184.00 .001 .430
Abbreviations: FEP, first episode of psychosis; LHVI, left hippocampal volumetric integrity; RHVI, right hippocampal volumetric integrity.
a Effect sizes were calculated using the z score statistic from eachMann-Whitney test comparison of median values, divided by the square root of the sample size.
Figure 1. Duration of Untreated Psychosis (DUP) and Annualized
Percentage Change in Left Hippocampal Volumetric Integrity (LHVI)
FromBaseline to Follow-up in ParticipantsWith First-Episode Psychosis
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The solid line represents the association between ranked values for LHVI and
DUP. Spearman rank correlation coefficient is shown.
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volume measured by the longitudinal stream of FreeSurfer,
version6, reflects thehigh reliability andsensitivityof theHVI
method for detecting pathologic change, as previously dem-
onstrated in Alzheimer disease.14,15 We confirmed the supe-
rior test-retest reliability of HVI in a publicly available set of
repeated scans of healthy individuals; the total coefficient of
variation for HVI was 0.43% vs 1.03% using the longitudinal
stream of FreeSurfer, version 6 (eAppendix 13 in the Supple-
ment). In addition, HVI is an estimate of relative (percentage)
hippocampal atrophy rather than of absolute hippocampal
volume and, hence, is less influenced by interindividual vari-
ability in brain volume. For example, in the current data set,
HVI was markedly less correlated with intracranial volume
(r = −0.19; P = .05) than was hippocampal volume measured
by FreeSurfer, version 6 (r = 0.69; P = 1.0 × 10−16) (eAppen-
dix 14 in the Supplement).
DUP andHVI
We found that the annualized rate of LHVI reduction in-
creased by 0.4%perweek of DUP across the full range of DUP
values (Figure 1). Previous studies have largely failed to iden-
tify morphologic correlates of DUP,9,35 although in a cross-
sectional study, Guo and colleagues36 found an inverse corre-
lation between DUP and hippocampal volume. Duration of
untreated psychosis was not independently associated with
baseline HVI in our sample, but DUP interacted with BDNF,
NOS1, COMT, and ZNF804A genotypes andwith 2 inflamma-
tory serum biomarkers in association with baseline LHVI.
HVI and Clinical Measures
Atbaseline, higher scores on theBPRSagitation subscalewere
associatedwith greater hippocampal atrophy (eTable 9 in the
Supplement) andwith greater reductionof LHVIduring treat-
ment (eTable 10 in the Supplement). Although reduced hip-
pocampal volumemayhave contributed to agitation, it is also
possible that stress, expressed behaviorally as agitation, con-
tributed to hippocampal volume loss.37 A rapid decrease in
LHVIwas also associatedwith less responseofnegative symp-
toms, suggesting a potential clinical consequence of hippo-
campalvolumechangeearly in treatment.However, these find-
ingsmust be considered exploratory because theywould not
survive correction for multiple comparisons.
Peripheral Biomarkers
At baseline,wedidnot finddifferences inmeasures of inflam-
mationandoxidative stressbetweenpatients andhealthycon-
trols, contrary to someother studies.25,38Wedid findelevation
of salivary cortisol concentrations in individualswithFEP, but
unlike the findingbyMondelli andcolleagues,23 salivary corti-
solconcentrationwasnotassociatedwithhippocampalvolume,
nor were genes involved in cortisol regulation (FKBP5 and
NR3C2; eTables 15 and 16 in the Supplement). In addition, as-
partate concentrations were elevated at baseline among indi-
viduals with FEP. Aspartate is an excitatory neurotransmitter
thatactsprimarilyatextrasynapticN-methyl-D-aspartaterecep-
tors that are associatedwithneurotoxicity39; however, neither
baseline aspartate concentrationsnor the increase inaspartate
concentrationswith treatmentwere correlatedwith LHVI.
Homocysteine
Antipsychotic treatment was associated with an elevation
of plasma homocysteine concentrations. Homocysteine is a
neurotoxicaminoacidthathasbeenassociatedwithhippocam-
pal volume loss in healthy elderly individuals40,41 and with
hippocampal injury and sensitization to oxidative stress and
excitotoxic effects in animalmodels.42 Homocysteine is a by-
product ofdopaminemetabolismbyCOMT,which is localized
primarily in astrocytes.43,44 Although the elevation of homo-
cysteineduringtreatmentwasnotcorrelatedwithLHVIchange,
homocysteineconcentrationswerecorrelatedwithamarker for
astrocytic injury (S100B)andwith inflammatory factors (IFN-γ
and IL-8) that, in turn, were correlatedwith LHVI.
Biomarkers AssociatedWith Baseline LHVI
TheinteractionofDUPwithseveralbiomarkerswassignificantly
associatedwith baseline LHVI, suggesting that theymay play
a role in thenegative associationof psychosiswithhippocam-
pal volume. These biomarkers included COMT genotype and
Table 3. Significant Results From LASSOMultivariate AssociationModel of Baseline and Change in LHVI
Baseline LHVI Factorsa
Parameter
Estimate SE 95% CI P Value
IL-8 −0.000273 0.0001146 −0.00049 to 4.816E−5 .02
IFN-γ 0.0003771 0.0001557 7.1923E−5 to 0.0006822 .02
NOS1 (CC) 0.0295961 0.0093529 0.0112649 to 0.0479274 .002
BDNF (GG) 0.0235826 0.0091729 0.005604 to 0.0415612 .01
IFN-γ × DUP 1.3282E-5 6.3559E-6 8.2421E−7 to 2.574E−5 .04
IL-8 × DUP 7.2689E-5 0.0000127 4.7779E−5 to 0.0000976 .001
NOS1 (CC) × DUP 0.0021139 0.0005374 0.0010606 to 0.0031673 .001
BDNF (AA) × DUP 0.002997 0.0009478 −0.004855 to 0.001139 .002
ZNF804A (GG) × DUP 0.0012497 0.0002708 0.000719 to 0.0017803 .001
COMT (GA) × DUP −0.00142 0.000502 −0.002404 to 0.000437 .005
Change in LHVI factors
S100B −0.016025 0.0016714 −0.019301 to −0.012749 .001
S100B × DUP −0.000801 0.000159 −0.001112 to −0.000489 .001
Thioredoxin × DUP −0.000159 2.7019E-5 −0.000212 to −0.000106 .001
NOS1 (CC) × DUP −0.241284 0.0811758 −0.400386 to −0.082182 .003
Abbreviations: BDNF, brain-derived
neurotrophic factor;
COMT, catechol-O-methyltransferase;
DUP, duration of untreatedpsychosis;
IFN-γ, interferon γ; IL-8, interleukin8;
LASSO, least absolute shrinkage
and selection operator; LHVI, left
hippocampal volumetric integrity;
NOS1, nitric oxide synthase 1;
S100B,S100calciumbindingproteinB;
ZNF804A, zinc finger protein 804A.
a Parenthetic capital letters CC, GG,
AA, and GA refer to genotypes.
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ZNF804A genotype; ZNF804A regulates expression of COMT
and of dopamine D2 receptors in the hippocampus.45 The in-
teractionofDUPwithother biomarkers, including the inflam-
matory biomarkers IL-8 and IFN-γ, the growth factor BDNF
genotype, and theNOS1 genotype, was associated with base-
line LHVI. Neuronal nitric oxide synthase is coupled to the
N-methyl-D-aspartate receptor and regulates the balance be-
tweenneuroplasticity, neurotoxicity, andpruning by regulat-
ing inhibitory andexcitatory transmitter release aswell as the
generation of nitrosyl free radicals.46-48 Brain-derivedneuro-
trophicfactordirectly influenceshippocampalneurogenesisand
supports dendritic arborization andplasticity.49 Thus, the as-
sociationbetweencumulativeexposure topsychosis (DUP)and
hippocampal volumeat baselinewasmediatedbybiomarkers
associatedwithdopamineandglutamate transmission, inflam-
mation, oxidative stress, andBDNF genotype, consistentwith
currentmodels of schizophrenia.10
Factors AssociatedWith Change in LHVI
The reduction in LHVI during treatment was associated with
baseline concentrations of S100B and thioredoxin. S100 cal-
cium binding protein B is a small calcium-binding molecule
released by glia in response to inflammation or oxidative
stress.26,50Thioredoxin is anantioxidantmolecule releasedby
astrocytes and neurons in response to oxidative stress.25 One
potential source of oxidative stress in psychosis is excessive
release of dopamine, which produces free radicals whenme-
tabolized by COMT.28 Antipsychotics may initially increase
dopamine levels in the hippocampus by antagonism of pre-
synapticautoreceptors in theCA1subfield.51The increasedhip-
pocampal dopamine release associated with antipsychotic
treatment may be time limited, however, since increased
antipsychotic-induced midbrain dopamine neuron firing is
attenuated after several weeks of sustained exposure.52
Limitations
Our sampleofparticipantswithFEPwashomogenouswith re-
spect to race/ethnicity and the absenceof substance abuse, so
these resultsmaynot generalize tomoreheterogeneouspopu-
lations. Furthermore, 56% of participants with FEP did not
complete follow-upatweek8—thismayhave introducedabias
toward hospitalized patients, as indicated by the higher rat-
ings of symptom severity in those who completed the study.
It is unclear to what degree peripheral biomarkers inform us
about the biochemical environment of the hippocampus be-
cause the origin of these biomarkers is not limited to the cen-
tral nervous system and access to the peripheral circulation
is limited by the blood-brain barrier.10 Finally, in the absence
of a placebo control, we are unable to determine from these
data whether the change in HVI was the result of illness pro-
gression or amedication effect, or both. Although our results
from peripheral biomarkers provide promising directions for
further research on mechanisms contributing to hippocam-
pal volume loss, these results must be considered explor-
atory, and the considerable heterogeneity among the partici-
pantswithFEP suggests thatmuch larger samples areneeded.
Conclusions
We found significantly lower HVI at baseline in participants
with FEP comparedwith healthy controls and additional HVI
reductionduring antipsychotic treatment that correlatedwith
DUP, consistentwith a persistent, possibly deleterious, effect
of untreated psychosis on brain structure. Our exploratory
analysis identifiedmolecularmechanismsbywhichDUPmay
affecthippocampalvolume.Larger longitudinal studiesof lon-
ger duration are needed to examine the association between
DUP, hippocampal volume, and clinical outcomes.
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fraction is estimated by histogram analysis.14
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